Table 4.
aAGREE-REX Scores For Specific Items, Overall Items (across the 11 Items), and Overall Assessments
| Practice Guidelines (PG) Features | Specific Items Means | Overall Means | Overall Assessments | # PGs |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evidence | Clinical Relevance | Patient/pop. Relevance | Implement-ation Relevance | Values Developers | Values Users | Values Patient/Pop | Values Policy | Alignment of Values | Local Applicability | Resources, Tools, Capacity | Mean Overall Score | % Score Mean | Clinical Credibility | Implement- ability | ||
| All Guidelines | 5.15 (1.33) | 5.47 (1.18) | 4.87 (1.33) | 4.46 (1.52) | 4.61 (1.45) | 4.28 (1.52) | 3.85 (1.61) | 3.44 (1.53) | 3.42 (1.44) | 3.56 (1.47) | 3.49 (1.44) | 4.23 (1.14) | 54 (19) | 4.78 (1.24) | 4.19 (1.23) | 161 |
| Type of Organization | ||||||||||||||||
| Government Supported | 5.61 (1.14) | 5.95 (0.8) | 5.57 (0.98) | 5.48 (0.89) | 5.26 (1.2) | 4.97 (1.14) | 4.83 (1.34) | 4.56 (1.15) | 4.11 (1.32) | 4.52 (1.3) | 4.41 (1.11) | 5.02 (0.77) | 67 (13) | 5.28 (0.96) | 4.85 (1.07) | 46 |
| Professional Societies | 4.98 (1.35) | 5.24 (1.26) | 4.57 (1.36) | 4.04 (1.55) | 4.30 (1.48) | 3.98 (1.58) | 3.41 (1.52) | 2.99 (1.46) | 3.1 (1.38) | 3.17 (1.39) | 3.06 (1.39) | 3.89 (1.2) | 48 (19) | 4.56 (1.31) | 3.89 (1.21) | 109 |
| Other or Not Clear | 4.83 (1.63) | 6.17 (0.68) | 5.00 (1.41) | 4.42 (1.24) | 5.17 (0.93) | 4.5 (1.38) | 4.42 (2.04) | 3.00 (0.89) | 3.75 (1.63) | 3.33 (0.82) | 4.25 (1.29) | 4.44 (0.99) | 57 (17) | 4.83 (0.82) | 4.50 (0) | 6 |
| p-value | 0.021 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.004 | <0.001 | |
| Country | ||||||||||||||||
| US | 5.06 (1.39) | 5.33 (1.28) | 4.68 (1.4) | 4.17 (1.58) | 4.51 (1.49) | 4.12 (1.62) | 3.61 (1.66) | 3.08 (1.47) | 3.31 (1.54) | 3.26 (1.47) | 3.22 (1.47) | 4.03 (1.21) | 51 (20) | 4.62 (1.31) | 3.98 (1.26) | 89 |
| UK | 5.26 (1.23) | 5.74 (0.9) | 5.22 (1.13) | 5.04 (1.25) | 4.86 (1.39) | 4.76 (1.21) | 4.23 (1.31) | 4.16 (1.41) | 3.66 (1.26) | 4.18 (1.48) | 4.12 (1.41) | 4.66 (0.95) | 61 (16) | 5.06 (1.06) | 4.51 (1.19) | 46 |
| Canada | 5.46 (1.21) | 5.87 (0.64) | 5.17 (1.19) | 4.75 (1.5) | 4.67 (1.51) | 4.5 (1.58) | 4.46 (2) | 3.87 (1.61) | 3.79 (1.48) | 3.83 (1.27) | 3.42 (1) | 4.53 (1.08) | 59 (18) | 4.92 (1.12) | 4.50 (1.1) | 12 |
| International | 5.18 (1.38) | 5.18 (1.44) | 4.64 (1.42) | 4.18 (1.47) | 4.39 (1.47) | 3.54 (1.31) | 3.64 (1.67) | 2.96 (1.39) | 2.96 (1.18) | 3.18 (0.99) | 3.25 (1.14) | 3.91 (0.98) | 49 (16) | 4.75 (1.38) | 4.21 (1.03) | 14 |
| p-value | 0.7 | 0.1146 | 0.1192 | 0.011 | 0.5495 | 0.025 | 0.0932 | <0.001 | 0.2609 | 0.0036 | 0.0056 | 0.0106 | 0.0106 | 0.2649 | 0.0851 | |
aMean (SD); US United States, UK United Kingdom, Implement implementability, Patient/Pop Patients/population